Innoviva (INVA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
2 figures withheld by our checks. Each blank figure names its reason.
94.3mn → 84.8mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
▲319% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
66¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 100.0% → 74.8%. Net margin 65.9% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 438,318.0 | 411,328.0 | 358,711.0 | 310,463.0 | 331,339.0 | 391,866.0 | ▲14.7% | +1.2% |
Cost of revenue | 111,820.0 | 103,661.0 | 62,500.0 | 64,424.0 | 13,793.0 | 0.0 | ▲65.9% | +95.9% (22→25) |
Gross profit | 326,498.0 | 307,667.0 | 296,211.0 | 246,039.0 | —A | 391,866.0 | ▲3.9% | — |
Research & development | 20,200.0 | 30,604.0 | 13,654.0 | 33,922.0 | 41,432.0 | 576.0 | ▲124.1% | +170.0% |
Selling, general & admin | 136,148.0 | 113,318.0 | 115,690.0 | 98,232.0 | 63,538.0 | 16,187.0 | ▼2.1% | +62.7% |
Total operating expenses | 156,348.0 | 143,922.0 | 129,344.0 | 132,154.0 | −2,858.0 | −74,267.0 | ▲11.3% | — |
Operating incomefeeds ROC rank | 170,150.0 | 163,745.0 | 166,867.0 | 113,885.0 | 320,404.0 | 466,133.0 | ▼1.9% | −23.0% |
Other income, net | 53,819.0 | 163,117.0 | −129,479.0 | 80,213.0 | −33,455.0 | −20,857.0 | — | — |
Pretax income | 223,969.0 | 326,862.0 | 37,388.0 | 194,098.0 | 286,949.0 | 445,276.0 | ▲774.2% | −7.4% |
Income tax | 30,529.0 | 55,697.0 | 13,996.0 | 14,376.0 | 66,687.0 | 76,439.0 | ▲297.9% | −7.6% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 193,440.0 | 271,165.0 | 23,392.0 | 179,722.0 | 220,262.0 | 368,837.0 | ▲1059.2% | −7.4% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.24 | 3.30 | 0.36 | 2.20 | 2.37 | 2.87 | ▲816.7% | +3.6% |
Diluted shares (mn) | 72.07 | 84.76 | 74.19 | 86.88 | 95.25 | 94.31 | ▲14.3% | −2.6% |
| Margins | ||||||||
Gross margin67th pct in Healthcare | 74.5% | 74.8% | 82.6% | 79.2% | —A | 100.0% | ▼7.8pp | — |
Operating margin | 38.8% | 39.8% | 46.5% | 36.7% | 96.7% | 119.0% | ▼6.7pp | −79.1pp |
Net margin98th pct in Healthcare | 44.1% | 65.9% | 6.5% | 57.9% | 66.5% | 94.1% | ▲59.4pp | −28.2pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Innoviva's revenue last fiscal year?
Innoviva reported revenue of $411.3M in fiscal 2025, up 14.7% from fiscal 2024.
What was Innoviva's net income?
Innoviva reported net income of $271.2M in fiscal 2025, a net margin of 65.9%.

